Ansbert Gadicke sold $241k of HOWL
owner at Werewolf Therapeutics, Inc.. 213,529 shares at an average of $1.13, traded Nov 7, 2025, filed Nov 12, 2025.
Score components
- +12Role10% owner
- +13Trade size$241k at market
- 0Share of holdings soldSold 3.6% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +0.9%, 3m -38.4%, 6m -46.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-25-000459, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2025 | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -68,480 | $1.11 | $76k | 5,836,240 | Nov 12, 2025 |
| Nov 10, 2025 | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -48,570 | $1.18 | $57k | 5,787,670 | Nov 12, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -55,810 | $1.14 | $64k | 5,731,860 | Nov 12, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -40,669 | $1.09 | $44k | 5,691,191 | Nov 12, 2025 |
Related signals
Other insiders at Werewolf Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $45k 143,199 shares | -100% | |
| 29Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $47k 157,084 shares | -52% | |
| 31Weak | Werewolf Therapeutics, Inc. | Ra Capital Management, L.p. owner | $146k 416,911 shares | -9% | |
| 31Weak | Werewolf Therapeutics, Inc. | Ra Capital Management, L.p. owner | $174k 448,836 shares | -9% | |
| 38Weak | Werewolf Therapeutics, Inc. | Ra Capital Management, L.p. owner | $254k 678,226 shares | -12% | |
| 13Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $28k 76,928 shares | -20% | |
| 14Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $43k 105,565 shares | -22% | |
| 16Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $64k 139,803 shares | -22% | |
| 16Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $66k 141,106 shares | -18% | |
| 17Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $87k 191,762 shares | -20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.